Genome-scale protein microarray comparison of human antibody responses in plasmodium vivax relapse and reinfection

Large scale antibody responses in Plasmodium vivax malaria remains unexplored in the endemic setting. Protein microarray analysis of asexual-stage P. vivax was used to identify antigens recognized in sera from residents of hypoendemic Peruvian Amazon. Over 24 months, of 106 participants, 91 had two symptomatic P. vivax malaria episodes, 11 had three episodes, 3 had four episodes, and 1 had five episodes. Plasmodium vivax relapse was distinguished from reinfection by a merozoite surface protein-3α restriction fragment length polymorphism polymerase chain reaction (MSP3α PCR-RFLP) assay. Notably, P. vivax reinfection subjects did not have higher reactivity to the entire set of recognized P. vivax blood-stage antigens than relapse subjects, regardless of the number of malaria episodes. The most highly recognized P. vivax proteins were MSP 4, 7, 8, and 10 (PVX-003775, PVX-082650, PVX-097625, and PVX-114145); sexual-stage antigen s16 (PVX-000930); early transcribed membrane protein (PVX-090230); tryptophanrich antigen (Pv-fam-a) (PVX-092995); apical merozoite antigen 1 (PVX-092275); and proteins of unknown function (PVX-081830, PVX-117680, PVX-118705, PVX-121935, PVX-097730, PVX-110935, PVX-115450, and PVX-082475). Genes encoding reactive proteins exhibited a significant enrichment of non-synonymous nucleotide variation, an observation suggesting immune selection. These data identify candidates for seroepidemiological tools to support malaria elimination efforts in P. vivax-endemic regions.